Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
About the SA-Author:
Edward Schneider is a managing director of Quan Management LLC. Mr. Schneider has over 20 years of investment experience, including 15 years managing technology funds in both quoted equities and venture capital. Prior to founding Quan Management in 2000, Mr. Schneider was a Geneva-based fund manager for Lloyds TSB Bank from 1994 to 2000, where he managed funds in excess of US$100 million as well as an external venture capital portfolio. From 1986 – 1994, Mr. Schneider was a buy-side equity analyst for Connecticut-based Wright Investors’ Service. Mr. Schneider holds a CFA designation, an MBA from Thunderbird and a BA from Emory University.
Description: Hedge fund manager.
Interests: Stocks - long, Stocks - short, Tech stocks
What will the Lonza deal be worth??
Celgene signs $500m antibody deal with Sutro
Joins list of companies with interest in antibody-drug conjugates
Celgene and Sutro Biopharma have agreed a deal worth up to $500m to develop novel antibody-drug conjugates bispecific antibodies for two undisclosed targets. The agreement will see antibody-focused Sutro use its cell-free protein synthesis technology for initial product design in the early research stages, with Celgene to support further development, regulatory and commercialisation efforts.
According to Sutro, it will receive a “substantial upfront payment” as part of the total $500m deal, which also includes an equity investment in the company and milestone payments. ”We are pleased to work with Celgene on multiple programmes that utilise a broad spectrum of Sutro’s cell free protein synthesis technology and capabilities,” said William Newell, chief executive officer of Sutro.
Dr Thomas Daniel, Celgene president, global research and early development, added, “We look forward to working with the team at Sutro and to exploring their platform’s potential to accelerate the discovery and development of superior multifunctional biologics.”
Antibody-drug conjugates are becoming an increasing area of interest for pharma companies who are interesting in exploiting their method of action, which involves a cancer cell-targeting antibody attached to a cytotoxic drug via a linking technology, allowing tumour cells to be targeted more directly over healthy cells.
This includes Abbott’s decision to expand its deal with Seattle Genetics to develop antibody-drug conjugates for several oncology targets.
Menarini also recently signed a €800m deal with Oxford BioTherapeutics to collaborate on the development of antibody-body based drugs for the treatment of several cancers.
In addition, Roche is involved in the advancement of antibody-drug conjugates with T-DM1, which has caused great excitement for its potential in the treatment of breast cancer.
http://www.pmlive.com/pharma_news/celgene_signs_$500m_antibody_deal_with_sutro_456329
Conjumab-A will be the key
Alzheimer’s Disease Drug Development Deserves Special Government Incentives Including Market Exclusivity
Dec 13 2012
I was invited to speak about vaccines at the 6th Annual Alzheimer’s Drug Discovery Summit in Philadelphia. The meeting provided an excellent forum for a group of academic opinion leaders and industry specialists to hold in-depth discussions regarding recent developments and work being conducted internationally in the field. Unquestionably, 2012 has been an important year that generated critically important clinical data, including the results of the beta amyloid antibody Phase 3 trials and the studies conducted by the Dominantly Inherited Alzheimer’s Network (DIAN) that likely will have a significant impact on the design of future Alzheimer’s clinical trials. At the same time, the fact that the two major sets of Phase 3 clinical trials failed to meet their primary objectives underscored the enormous challenges that lie ahead, including the need to start treatments far earlier, likely when the first symptoms appear or perhaps several years before the onset of symptomatic disease.
The summit was organized by CBI in consultation with Marc Cantillon, MD, Wellness Managements LLC, and former Executive Director, Critical Path Institute Coalition Against Major Diseases (CAMD).
The first day of the conference was chaired by Johan Luthman, PhD, Senior Program Leader Neuroscience R&D, Franchise Integrator at Merck who also spoke about qualification of diagnostic and prognostic biomarkers for AD. Dr. Luthman emphasized the role of biomarkers as essential tools to support diagnosis of early stage AD, offering possibilities to detect prodromal, pre-dementia, stages of the disease and the potential to identify even presymptomatic patients at risk of developing the disease. In addition, Dr. Luthman described how in various natural progression studies, some biomarkers also have been shown to be good predictors of the clinical rate of disease progression (e.g. conversion to dementia), and explained how this link provides opportunities to allowing further stratification of trial populations, as well as evaluate novel therapeutics in populations that previously could not be entered into trials.
The opening address was by John C. Morris, MD, Friedman Distinguished Professor of Neurology, Director Knight Alzheimer’s Disease Research Center, Washington University School of Medicine. As Professor Morris explained, the initial publication of cross-sectional results from DIAN validate the use of Alzheimer’s biomarkers to identify preclinical AD as only mutant carriers demonstrated biomarker abnormalities. Although preliminary, the findings propose an instructive timeline for the pathophysiology of preclinical AD, beginning with elevated CSF Ab that presumably is present at birth but at perhaps 20-25 years prior to onset of symptomatic AD, begins to decline. The DIAN study will provide the infrastructure for randomized, placebo-controlled secondary prevention trials of mechanism-based therapies in dominantly inherited AD. Three drugs have been selected for an initial trial, including gantenerumab (Roche), a monoclonal antibody that binds to all forms of aggregated beta amyloid and currently in prodromal Phase 2/3 trials; solanezumab (Eli Lilly & Co), a monoclonal antibody that binds to soluble forms of beta amyloid, which is to be tested in additional Phase 3 trials; and a BACE inhibitor from Eli Lilly that targets beta amyloid, theoretically reducing the production of beta amyloid and slowing the accumulation of plaques in the brain. Although dominantly inherited AD occurs in only about 1 percent of the population, most experts believe the lessons learned from these trials will have widespread utility and may be applied to testing therapeutics in a much broader population.
J. Michael Ryan, MD, Vice President and Head Neurodegeneration Clinical Science Unit at Novartis moderated a Roundtable Discussion starting with his personal perspective of how recent results will reshape the design and conduct of future AD clinical trials, as well as the allocation of resources devoted to Alzheimer’s research. Dr. Ryan highlighted what had been a recurring theme throughout the conference regarding how the industry will address the major challenges ahead.
I had recommended the organizers of the conference invite John Repas MD, PhD, Director of Policy at the Neurotechnology Industry Organization (NIO), a global trade association representing companies involved in commercial neurosciences, brain research institutes and patient advocacy groups.
In his address, Dr. Repas outlined federal policy levers to foster innovation and address public health in AD, especially focused on the NIO-sponsored National Neurodegenerative Disease Incentive, which aims to address the widening gap between prevalence and treatment in neurodegenerative disease conditions, such as AD, Parkinson’s and others that are causing massive public health and economic burdens. Dr. Repas said the prospects for advancing new therapies to practice are imperiled by the unique length and expense of clinical trials needed to demonstrate safety and efficacy in these diseases. Because of the slowly progressing nature of neurodegenerative diseases, the additional development time consumes both patent protection and defers market entry. It also has led many investors and developers to abandon disease-modifying approaches entirely.
I fully concur with NIO’s belief that the solution to this problem lies in creating a new market exclusivity for sponsors of novel disease-modifying therapeutics that are targeted to neurodegenerative disease, especially AD. The rationale of the NIO initiative follows that of the 1983 Orphan Drug Act, which has since spurred development of new medicines for hundreds of orphan diseases that, otherwise, would not have been addressable given the small market size. A guaranteed market exclusivity period of ten years would be sufficient to tilt the cost-benefit consideration toward continuing drug development for neurodegenerative diseases.
Much has been made about the recent decision of the Obama Administration to push for a $156 million increase in funding for Alzheimer's research over the next two years. Its proponents, especially the Alzheimer’s Association, should be lauded for their commitment to the cause. However, the size of the award is just a drop in the bucket that, in my opinion, will do very little, if anything, to alleviate the situation. Sadly, it underscores a gross lack of understanding on Capitol Hill regarding the needs of the research community -- including industry -- to identify new drugs and advance them through clinical trials as the only way to prevent a catastrophic socio-economic disaster, as more and more Americans are affected by this disease. One wonders how those government officials involved in this decision would feel about the impact of allocating similar funds, barely sufficient to purchase a single stealth bomber, to the overall security of the nation.
I would urge all to support the NIO initiative.
--Daniel Chain, Chairman and CEO, Intellect Neurosciences, Inc.
http://www.intellectns.com/blog
BID/ASK 0,02/0,019
Intellect Neurosciences CEO Daniel Chain to Discuss Vaccine Program at Alzheimer's Drug Development Summit
NEW YORK, Dec 6, 2012 (GlobeNewswire via COMTEX) -- Intellect Neurosciences, Inc. announces Dr. Daniel G. Chain, Chairman and CEO, will discuss Intellect's vaccine program at the Alzheimer's Drug Development Summit on December 11-12, 2012 at the Doubletree Center City in Philadelphia, PA where he has been invited as a Distinguished Speaker.
Dr. Chain's presentation, titled "Recent Advancements in Vaccine Development for AD Prophylaxis and Management," begins at 2:15 PM (EST) on December 12. The presentation reviews the challenges associated with the development of a safe and effective Alzheimer's vaccine and describes the rationale in support of Intellect's ground-breaking approach. The company's lead vaccine, RV03, is a first-in-class chimeric peptide vaccine targeting both amyloid beta and delta tau, a particularly pathogenic form of the protein that precedes tangle formation.
"Some suggest that disease-modifying treatments of Alzheimer's disease may ultimately be more expensive than palliative care," said Dr. Chain. "Therefore, the utility of a vaccine for Alzheimer's disease may prove to be the most cost-effective means to manage the disease and alleviate the suffering of millions of people and their families worldwide while also reducing the burden to healthcare systems."
About Intellect Neurosciences
Intellect Neurosciences, Inc., develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com .
Safe Harbor Statement Regarding Forward-Looking Statements:
The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward--looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward--looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Intellect's Quarterly Report on Form 10-Q (file no. 333--128226), filed on November 20, 2012.
This news release was distributed by GlobeNewswire, www.globenewswire.com
http://www.marketwatch.com/story/intellect-neurosciences-ceo-daniel-chain-to-discuss-vaccine-program-at-alzheimers-drug-development-summit-2012-12-06?reflink=MW_news_stmp
AesRx sees positive data of sickle cell drug candidate
[November 27, 2012]
Newton biotech AesRx LLC said data of Aes-103 shows that the drug treatment is safe and well-tolerated for patients with sickle cell disease, a blood disorder in which the sickle cells cause blood flow problems, severe pain and can lead to serious and life-threatening conditions.
AesRX said it will present data from its Phase 1 study of Aes-103 — which has already won orphan drug status from the U.S. Food and Drug Administration — at the 2012 American Society of Hematology (ASH) meeting in Atlanta.
The clinical trial was done in collaboration with the National Institutes of Health to research the effects of single doses of Aes-103 at various levels.
The studies are part of an ongoing collaboration which began in May involving AesRx and two separate parts of the NIH, the National Heart, Lung, and Blood Institute (NHLBI) and the National Center for Advancing Translational Sciences (NCATS).
Based on the results, AesRx has initatiated a second trial enrolling patients with sickle cell disease at the NIH Clinical Center in Bethesda, Md.
“We are very pleased with the results of our Phase 1 study,” said AesRx’s CEO Stephen Streiler in a statement. “In sickle cell patients, increasing the oxygen affinity of hemoglobin is known to prevent red blood cell sickling. The ability of Aes-103 to provide protection in a hypoxia challenge of healthy volunteers indicates biological activity in humans in a manner consistent with Aes-103’s proposed mechanism of action in sickle cell disease.”
AesRx is one of a small group of companies and projects focused on sickle cell. Cambridge-based Bluebird bio is focused on a treatment for betathalassemia (a blood disorder) and sickle cell anemia. A group of researchers have developed a device that measures blood flow and could potentially help physicians monior sickle cell patients. The MIT, Harvard University, Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital researchers recently applied for a patent on the technology and plan to develop it as a diagnostic and research tool.
http://www.masshightech.com/stories/2012/11/26/daily21-AesRx-sees-positive-data-of-sickle-cell-drug-candidate.html
AesRx to Present Phase 1 Data on Anti-Sickling Agent Aes-103 at ASH
NEWTON, MA, November 27, 2012—AesRx announced it will present data from the recently completed Phase 1 study of its anti-sickling agent Aes-103 at the 2012 American Society of Hematology (ASH) meeting in Atlanta. The data will be presented in a poster session on December 10.
Data shows the drug is safe and well-tolerated. It also shows Aes-103 is biologically active in humans in a manner consistent with its proposed mechanism of action in sickle cell disease.
The first-in-human, double-blind, placebo-controlled clinical trial was conducted in collaboration with the National Institutes of Health (NIH). The trial examined the effects of single doses of Aes-103 at 300 mg, 1000 mg, 2000 mg and 4000 mg or placebo in 20 healthy normal volunteers of African-American descent. Endpoints were focused on safety, pharmacokinetics and pharmacodynamic changes.
The safety measures showed no clinically significant adverse effects on vital signs, ECGs, clinical laboratory tests, physical exams or adverse events. All adverse events were mild and transient. The pharmacokinetics of Aes-103 showed 5-10 fold higher drug concentrations in red blood cells, which is the site of action of Aes-103 on hemoglobin, compared to drug concentrations in plasma. Aes-103 was rapidly absorbed and the amount of Aes-103 in plasma and red blood cells was largely dose proportional.
Pharmacodynamic effects were also examined to determine the ability of Aes-103 to increase the oxygen affinity of the hemoglobin of the healthy volunteers. In a hypoxia challenge test, the subjects inhaled low levels of oxygen (12%) while their blood oxygen levels (SpO2%) were monitored. Aes-103 in 1000-4000 mg doses reduced the hypoxia-related drop in subjects’ SpO2% compared to placebo and the 300 mg dose.
“We are very pleased with the results of our Phase 1 study,” commented Stephen R. Seiler, AesRx’s Chief Executive Officer. “In sickle cell patients, increasing the oxygen affinity of hemoglobin is known to prevent red blood cell sickling. The ability of Aes-103 to provide protection in a hypoxia challenge of healthy volunteers indicates biological activity in humans in a manner consistent with Aes-103’s proposed mechanism of action in sickle cell disease.”
Based on these positive results, a second trial of similar design enrolling patients with sickle cell disease has been initiated at the NIH Clinical Center in Bethesda, MD and is currently ongoing (see http://www.clinicaltrials.gov/ct2/show/NCT01597401?term=aes-103&rank=1).
The reported Phase 1 study and the ongoing Phase 1/2a study in sickle cell patients are part of a multi-institute, public-private translational research collaboration involving AesRx and two separate NIH components—the National Heart, Lung, and Blood Institute (NHLBI) and the National Center for Advancing Translational Sciences (NCATS) through its Therapeutics for Rare and Neglected Diseases (TRND) program.
About AesRx
AesRx is a biopharmaceutical company dedicated to the development of treatments for two orphan diseases. The Company’s lead program (Aes-103) is targeted to the treatment of sickle cell disease. Sickle cell disease is a recessive disorder of the hemoglobin which can lead to a wide range of serious, sometimes life-threatening, conditions including: chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, and cumulative damage to tissues and organs. More than 13 million individuals world-wide are afflicted with sickle cell disease. Aes-103 works by increasing the affinity of sickle hemoglobin for oxygen. Because only red blood cells with no bound oxygen will sickle, increasing the ability of the sickle red blood cells to bind oxygen reduces the number of cells that can sickle. AesRx is developing Aes-103 in collaboration with the National Institutes of Health. AesRx’s second development program, Aes-210, is targeted to treat certain inflammatory diseases of the lower intestine, including distal ulcerative colitis, pouchitis and radiation induced proctitis.
For more information about AesRx and Aes-103, see AesRx.com.
This press release contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio, pipeline and clinical programs (collectively the “Products”) of AesRx LLC (the “Company”), the market opportunities for the Products, the potential effectiveness of the Products based on the interpretation of past and/or planned pre-clinical or clinical data and the Company’s goals and objectives. These statements are subject to numerous risks and uncertainties.
This press release contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio, pipeline and clinical programs (collectively the “Products”) of AesRx LLC (the “Company”), the market opportunities for the Products, the potential effectiveness of the Products based on the interpretation of past and/or planned pre-clinical or clinical data and the Company’s goals and objectives. These statements are subject to numerous risks and uncertainties.
http://www.aesrx.com/news.html#ASH
Dr. Daniel Chain expect to complete testing and optimization the IgG4 humanized antibody in 2012. Sep 19, 2012: ILNS Announce Humanization of Next-Generation Monoclonal Antibody.
About CONJUMAB-A:
Antibody drug conjugates are a novel class of therapeutics with multiple applications to treat a broad spectrum of diseases. While current immunotherapy approaches attack the antibodies, they do not appropriately guard against the side effects, such as inflammation, that often comes with treatment. Most commonly seen in the treatment of certain types of cancer, Intellect Neurosciences’ newest treatment platform, CONJUMAB-A, applies the antibody drug conjugate approach to neurological disease. Intended to overcome the limitations of current passive immunotherapy approaches, the CONJUMAB-A platform increases clearance of amyloid proteins while delivering cytoprotective molecules to areas of the brain and other organs that may have been damaged as a result of these infirmities. One example of CONJUMAB-A’s cytoprotective mechanism is the reduction of inflammation caused by amyloidosis (the abnormal deposit of beta amyloid in the brain or other organs, which can result in plaque or lesions), while avoiding vasogenic edema, a common side effect of plaque dissolution that occurs in some patients. This approach has applications both in the therapeutic arena in diseases such as Alzheimer’s, Parkinson’s, Huntington’s, Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy, Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick’s disease, Cortical Basal Degeneration and Peripheral Amyloidosis. It also has tremendous potential for in vivo imaging of beta amyloid in the brain.
Intellect Neuroscience’s flagship CONJUMAB-A molecule, IN-N01-OX2, is a non-activating, stabilized IgG4 humanized antibody specific for beta amyloid protein (IN-N01, Intellect’s lead ANTISENILIN molecule) conjugated to as small molecule with neuroprotective properties. While lead testing and optimization is expected to be complete in 2012, IN-N01-OX2 is expected to enhance the clearing capacity of IN-N01, deliver on-site protection against beta amyloid neurotoxicity and prevent interaction with the melatonin receptor.
http://www.intellectns.com/platform-technologies/conjumab-a
Intellect Neurosciences and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer's Patients
Sep 19, 2012, 9:35 AM EDT
Lonza and Intellect Neurosciences Announces Intellect's Intention to Award Production of Its Antibody Drug Conjugate, CONJUMAB-A to Lonza
Sep 27, 2012, 9:35 AM EDT
Intellect Neurosciences and iNovacia Enter Research Service Agreement to Evaluate Lead Compounds for CONJUMAB-A Program
Oct 3, 2012, 9:35 AM EDT
Buy Volume 403,000
Intellect is not Pink anymore!
Daniel Chain Sues Pfizer for $2M
October 17, 2012 at 6:32 am
Intellect Neurosciences has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology.
Intellect Neurosciences was founded by CEO Daniel Chain, who laid the groundwork for the technology in dispute with Pfizer during his tenure at Mindset, a Jerusalem-based startup.
Intellect contends that the licensing fee was triggered when the U.S. Patent and Trademark Office issued the company a patent on May 8 that covers its Antisenilin monoclonal antibody platform technology for the treatment and prevention of Alzheimer’s disease.
“It’s a distressing situation for us, a small company, to go head-to-head with a major company,” Intellect Neurosciences Chairman and CEO Daniel Chain said in a report to The Pink Sheet. The milestone payment “was clear, black and white in the agreement.”
Intellect Neurosciences’ patent discloses therapeutic antibodies to treat or delay onset of Alzheimer’s disease. The antibodies bind to both ends of the beta amyloid protein without binding to the amyloid precursor protein.
Following the recent American Neurology Association annual meeting, Chain posted an Oct. 9 personal perspective on the conference on the company’s homepage. “As the dust settles after the initial disappointing results from four major Alzheimer’s Phase III trials,” he concludes, the ANA “offered glimmers of light that renewed hope. The presenters and expert panelists conveyed a strong sense that Intellect is correct in its belief beta amyloid (Aß) plays a central and causative role in the pathogenesis of Alzheimer’s disease and that immunotherapy represents a realistic path forward. The next-generation drugs will have an improved probability of success because of the lessons we have learned.”
http://www.bioisrael.com/daniel-chain-sues-pfizer-for-2m
Who will be the major partner for CONJUMAB-A license?
Novartis, Teva....
Maybe we will see 0,05 this week without news
Indeed! Do you know the ILNS share structure history before the split?
NEW ILNS LONZA Article
http://www.in-pharmatechnologist.com/Processing/Lonza-to-make-antibody-conjugates-for-preclinical-trials?utm_source=copyright&utm_medium=OnSite&utm_campaign
"While it is hard to say how significant the Intellect contract is for Lonza - no financial terms were disclosed - the deal does underline the growing interest top tier contract manufactoring organisations (CMOs) have in ADC development and manufacture."
Lonza took a 475M CHF credit and i read that Sabic and BASF interested to buy them.
About Lonza:
Company History
1897 Foundation of Lonza AG Electricity Works in Gampel, Valais (Switzerland), on the banks of river Lonza. The electricity was used to manufacture calcium carbide and acetylene.
1909 Lonza moves to Visp and manufactures synthetic fertilizers out of nitrogen, ammonia and calcium carbide.
1920 Production of nitric acid, ketene, and diketene starts.
1956 Start of Production of Niacin, a vitamin of the B-group.
1965 Change of the raw material base from carbide to naphtha and further development of backwards integration: intermediates and additives for pharmaceuticals, agrochemicals, dyestuffs, colours, adhesives, etc.
1969 Lonza expands to the USA and starts its business with chemical specialties.
1974 Merger with Alusuisse and development into an internationally operating enterprise.
1980 Lonza starts its biotechnological business.
1982 Start of exclusive manufacturing of substances for pharmaceutical and agrochemical companies.
1992 Lonza acquires a biotechnological production facility (fermentation) in the Czech Republic.
1996 In Guangzhou, China, a joint venture is signed to build up a niacinamide plant primarily to satisfy the regional market needs.
1996 Lonza acquires Celltech Biologics (GB and USA) and expands into the business with mammalian cell cultures and monoclonal antibodies.
1999 Lonza is de-merged from the Alusuisse-Lonza Group and listed as an independent company at the Swiss stock exchange.
2004 Lonza starts-up three 20’000-liter mammalian cell culture fermentation reactors in Portsmouth, NH (USA), the biggest single investment in its history.
2005 Lonza announces a significant investment program in the expansion of its peptides manufacturing capacities in its production site in Visp, Switzerland.
2006 Lonza carries out a series of strategic transactions aimed at transforming the company into one of the world’s leading suppliers of active pharmaceutical ingredients, biopharmaceuticals and research products to the pharmaceutical, healthcare and life-science industries.
Acquisition of Bioproducts manufacturing division of UCB (Braine-L’Alleud, Belgium) positions Lonza as a leading global provider of peptides to the biopharmaceutical market.
The fourth 20’000-liter bioreactor in Portsmouth, NH (USA) came on stream.
IPO of Polynt S.p.A., Lonza’s Polymer Intermediates business. Lonza retains a minority stake in Polynt.
Lonza announces the acquisition of the complementary Bioproducts and Biopharma businesses from Cambrex to further enhance Lonza’s capability to service the needs of the highgrowth life sciences R&D and pharmaceutical development industries. The acquisition also expands Lonza’s geographical footprint, particularly in the USA.
Agreement with Genentech, one of the world’s largest biotechnology companies, to acquire mid-scale biopharmaceutical manufacturing operation in Porriño, Spain, providing significant manufacturing capacity two years earlier than planned. In addition, Lonza will build and start up a large-scale mammalian biopharmaceutical facility in Singapore which Genentech will have an exclusive option to buy upon US FDA licensure. In parallel, Lonza will build its own planned large-scale (4 x 20’000-liter) biopharmaceutical manufacturing facility in Singapore.
2007 Lonza announced that it has completed the acquisition of the Research Bioproducts business and the Microbial Biopharmaceutical business of the US company Cambrex, published in October 2006.
Lonza announced the acquisition of the assets of S.A.M. Electron Technologies based in Shawinigan (Canada). The acquisition of these assets is concurrent with an exclusive worldwide license for a cerium mediator electrochemical technology (CeTECH™) from Hydro-Québec and lease agreement with the City of Shawinigan. CeTECH™ is an electrochemical cerium based oxidation technology which can be used to produce a variety of high value added compounds. It has been demonstrated on a commercial scale for the production of vitamin K-3.
Lonza finalizes the divestiture of its purified isophthalic acid plant in Singapore.
2008 Lonza finalizes the selling of the majority of its shares in Polynt S.p.A.
Lonza completes the acquisition of amaxa. The acquisition of amaxa is in line with Lonza’s strategy of growing its life-science platform. amaxa is a premium supplier to the cell discovery market with leading edge, proprietary technologies in well-defined market niches of transfection systems. The deal further strengthens Lonza’s position as a worldwide leader in cell discovery by integrating this unique, proprietary technology into its portfolio and by continuing to develop the company’s activities.
2009 Teva and Lonza announced their agreement to establish a joint venture to develop, manufacture and market a portfolio of biosimilars.
Lonza strengthens its protein design technology offering for biopharmaceutical development by acquiring Algonomics NV (Gent, Belgium).
Lonza expands its cell-biology platform by acquiring Simbiosys Biowares’ preclinical cell and molecular biology group.
2010 Lonza expands its capacities for Carnipure™ and Carniking™ by investing in a new manufacturing facility for L-carnitine products in Nansha.
Lonza invests in new plant for vitamin B3 (nicotinates) in Nansha.
Lonza Group Ltd acquires MODA Technology Partners ("MODA"), a software company that provides paperless quality control solutions. The acquisition will strengthen the Rapid Testing Solutions platform of Lonza’s Bioscience division by adding a complementary product offering for quality assurance (QA) and quality control (QC) organizations in the life-science industry.
Lonza acquires viral vaccine and vector manufacturer Vivante GMP Solutions. The acquisition advances Lonza’s strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets.
Lonza signs agreement with GlaxoSmithKline (GSK) to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio. Thereby Lonza will supply manufacturing capacity for five early stage monoclonal antibodies.
Lonza acquires biotech service provider Algonomics, a contract research organization providing integrated immunogenicity prediction services to support companies in the development of biotherapeutics.
2011 Lonza invests £16 million to further develop the flexibility and capability of its Slough, UK biopharmaceutical manufacturing facility to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing. The project is scheduled for completion by the end of 2012.
Lonza plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in Visp, Switzerland to serve growing oncology API market. Cytotoxic APIs are commonly used in oncology therapeutics, which represent one of the fastest growing segments of the pharma and biotech industry.
Lonza expands its viral-based therapeutics business with the construction of a new, state-of-the-art cGMP clean room located adjacent to its existing Houston, Texas operations.
Lonza is investing CHF 10 million to expand its biopharmaceutical development services platform in Singapore to meet increasing demand for biopharma development services from preclinical to commercial.
Lonza invests CHF 5.8 million in a formulation plant for Meta™ metaldehyde. This will enable Lonza to supply its own formulations, allowing the company in the future to serve the market not only with metaldehyde as an active substance, but also with ready-made slug pellets. It is expected to become operational in the second half of 2012.
Lonza celebrates 40 years as leading producer of vitamin B3. Since 1971, Lonza has supplied more than half the world’s demand for vitamin B3 in the human and animal health nutrition industries.
Lonza Group Ltd and global regenerative medicine company Mesoblast Limited enter into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf (allogeneic) adult stem cell products.
Lonza acquires Arch Chemicals, Inc., a global biocides company providing innovative solutions to destroy or to selectively inhibit the growth of harmful microorganisms, to create the world’s leading Microbial Control business. The combined businesses will be able to develop innovative microbial control formulations based on a broad portfolio of registered and approved active ingredients. Jeanne Thoma is appointed to Chief Operating Officer for Lonza’s Microbial Control sector (LMC) which will be created following the acquisition.
Lonza Group Ltd (SIX stock code: LONN VX; SGX-ST stock code: O6Z) makes its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 21 October 2011 and consequently is the first SIX Swiss-listed company to dual list in Singapore.
Lonza to expand early phase manufacturing capacity at its site in Nansha, China, to serve small molecules market.
What PR today?
I read the news now, back from a short trip to spain via swissair...
Will post it on a german trading portal wallsreet-online.de.
This is huge!
Outstanding news:
- n-terminus patent
- milestone payment Pfizer, about 2M
- milestone payment Viropharm, about 10M
- ....and the new deal
Look for the patent history (genentech).
Maybe that's the key. Ask bioguru for detail information!
That's true!!!
MM's playing
RELOAD NOW!
Good man... but ILNS time will come soon!
IMO
Good analysis Jonny, this Austrian keep an eye on you in future.
What do you see for the next weeks?
0,022/0,03
More than enough fantastic News outstanding...this will hype!
Chance to reload before news...
Ilns is a damn good deal for 0,05!
This could be a 100M company soon.